SIC
HQL

Samalin Investment Counsel’s abrdn Life Sciences Investors HQL Stock Holding History

Samalin Investment Counsel’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,546
Closed -$288K – 325
2025
Q3 		$288K Sell
18,546
-3,236
-15% -$44.3K 0.1% 254
2025
Q2 		$279K Buy
21,782
+1,366
+7% +$16.8K 0.11% 259
2025
Q1 		$259K Buy
+20,416
New +$276K 0.11% 260

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Samalin Investment Counsel's HQL Position: Q4 2025 in Review

Samalin Investment Counsel sold out of abrdn Life Sciences Investors (HQL) in Q4 2025, closing a stake of 18,546 shares — an estimated $288K sold.

Samalin Investment Counsel first reported a position in HQL in Q1 2025 and held it in 3 quarters. The position peaked at $288K in Q3 2025. 73 funds tracked by Wall St. Rank hold HQL as of Q4 2025.

  • Samalin Investment Counsel reported no remaining abrdn Life Sciences Investors position as of Q4 2025 after selling out during the quarter.
  • Samalin Investment Counsel sold 18,546 abrdn Life Sciences Investors shares in Q4 2025, an estimated $288K.
  • Samalin Investment Counsel first reported a position in abrdn Life Sciences Investors in Q1 2025 and held it in 3 quarters.
  • Samalin Investment Counsel's abrdn Life Sciences Investors position peaked at $288K in Q3 2025.
  • 73 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2025.

Based on Samalin Investment Counsel's 13F filing for Q4 2025, filed 30 Jan 2026.